Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28626698 | 0.79 | FFAR1 (0.48) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL2984826 | 0.76 | SMN1; SMN2 (0.32) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL21246105 | 0.76 | TSHR (0.33) | TSHR | |
| SCHEMBL25248520 | 0.74 | KDM4E (0.31) | KDM4EFFAR1CPT2TDP1 | |
| SCHEMBL17999714 | 0.73 | CYP2C19 (0.33) | TSHRCYP2C19 | |
| SCHEMBL13104241 | 0.73 | FFAR1 (0.42) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL1978416 | 0.73 | CETP (0.48) | TDP1TSHRCYP2C19HIF1A | |
| SCHEMBL1455701 | 0.70 | GRM4 (0.32) | — | |
| SCHEMBL25381004 | 0.69 | BTN3A1 (0.30) | — | |
| SCHEMBL23671685 | 0.69 | ALDH1A1 (0.50) | FFAR1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550125-B2 | Prodrugs of imidazotriazine compounds as CK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180305364-A1 | PRODRUGS OF IMIDAZOTRIAZINE COMPOUNDS AS CK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-25 | — | — | US | disclosed |
| WO-2017070135-A1 | PRODRUGS OF 2-(4-(3-((4-AMINO-7-CYANO-IMIDAZO[2,1-F][1,2,4]TRIAZIN-2-YL)AMINO)PHENYL)PIPERAZ IN-1-YL)PROPANAMIDE DERIVATIVES AS CK2 INHIBITORS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8426388-B2 | Prodrugs of HIV protease inhibitors | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-1773850-B1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LAB (US) | 2013-01-30 | — | — | EP | disclosed |
| EP-2336138-A2 | Prodrugs of HIV protease inhibitors | ABBOTT LABORATORIES (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100286032-A1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| US-7718633-B2 | Prodrugs of HIV protease inhibitors | ABBOTT LABORATORIES (US) | 2010-05-18 | — | — | US | disclosed |
| US-20070270383-A1 | Prodrugs of HIV protease inhibitors | ABBVIE INC. | 2007-11-22 | — | — | US | disclosed |
| EP-1773850-A2 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014282-A2 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305364-A1 | PRODRUGS OF IMIDAZOTRIAZINE COMPOUNDS AS CK2 INHIBITORS | CSNK2A1, CSNK1A1, CSNK2A2 | KDM4E 1956/4885FFAR1 1193/4885CPT2 3402/4885 |
| US-20100286032-A1 | PRODRUGS OF HIV PROTEASE INHIBITORS | PREP, PEPD, SERPINB1 | KDM4E 2100/4885FFAR1 3151/4885CPT2 4615/4885 |
| US-20070270383-A1 | Prodrugs of HIV protease inhibitors | PREP, PEPD, SERPINB1 | KDM4E 2100/4885FFAR1 3151/4885CPT2 4615/4885 |
| US-10550125-B2 | Prodrugs of imidazotriazine compounds as CK2 inhibitors | CSNK1A1, CSNK2A1, CSNK2A2 | KDM4E 1618/4885FFAR1 1052/4885CPT2 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.